Xiamen Amoytop Biotech Co., Ltd.

SHSE:688278 Stock Report

Market Cap: CN¥28.8b

Xiamen Amoytop Biotech Past Earnings Performance

Past criteria checks 5/6

Xiamen Amoytop Biotech has been growing earnings at an average annual rate of 45.6%, while the Biotechs industry saw earnings growing at 7.6% annually. Revenues have been growing at an average rate of 27.7% per year. Xiamen Amoytop Biotech's return on equity is 32.7%, and it has net margins of 28.5%.

Key information

45.6%

Earnings growth rate

44.9%

EPS growth rate

Biotechs Industry Growth11.3%
Revenue growth rate27.7%
Return on equity32.7%
Net Margin28.5%
Last Earnings Update30 Sep 2024

Recent past performance updates

Xiamen Amoytop Biotech (SHSE:688278) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Apr 04
Xiamen Amoytop Biotech (SHSE:688278) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Recent updates

Xiamen Amoytop Biotech Co., Ltd.'s (SHSE:688278) 26% Jump Shows Its Popularity With Investors

Sep 19
Xiamen Amoytop Biotech Co., Ltd.'s (SHSE:688278) 26% Jump Shows Its Popularity With Investors

Investors Appear Satisfied With Xiamen Amoytop Biotech Co., Ltd.'s (SHSE:688278) Prospects As Shares Rocket 26%

Sep 19
Investors Appear Satisfied With Xiamen Amoytop Biotech Co., Ltd.'s (SHSE:688278) Prospects As Shares Rocket 26%

Is There An Opportunity With Xiamen Amoytop Biotech Co., Ltd.'s (SHSE:688278) 50% Undervaluation?

Jun 12
Is There An Opportunity With Xiamen Amoytop Biotech Co., Ltd.'s (SHSE:688278) 50% Undervaluation?

Xiamen Amoytop Biotech (SHSE:688278) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Apr 04
Xiamen Amoytop Biotech (SHSE:688278) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Xiamen Amoytop Biotech Co., Ltd.'s (SHSE:688278) Share Price Could Signal Some Risk

Mar 25
Xiamen Amoytop Biotech Co., Ltd.'s (SHSE:688278) Share Price Could Signal Some Risk

Revenue & Expenses Breakdown

How Xiamen Amoytop Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

SHSE:688278 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 242,5957411,271279
30 Jun 242,3876581,179265
31 Mar 242,2266001,126234
31 Dec 232,1005551,058229
30 Sep 231,843456951190
30 Jun 231,716356921174
31 Mar 231,601314867166
31 Dec 221,527287840149
30 Sep 221,466254852124
30 Jun 221,37824383293
31 Mar 221,26220477283
31 Dec 211,13218169880
30 Sep 211,04316862986
30 Jun 2190414255279
31 Mar 2182212850676
31 Dec 2079411750374
30 Sep 207629849557
30 Jun 207719549557
31 Mar 207718650552
31 Dec 197306448550
30 Sep 196655844150
31 Dec 184481631938
31 Dec 17323525518
31 Dec 16280292039

Quality Earnings: 688278 has a high level of non-cash earnings.

Growing Profit Margin: 688278's current net profit margins (28.5%) are higher than last year (24.7%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 688278's earnings have grown significantly by 45.6% per year over the past 5 years.

Accelerating Growth: 688278's earnings growth over the past year (62.6%) exceeds its 5-year average (45.6% per year).

Earnings vs Industry: 688278 earnings growth over the past year (62.6%) exceeded the Biotechs industry 1.3%.

Return on Equity

High ROE: 688278's Return on Equity (32.7%) is considered high.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 04:47
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Xiamen Amoytop Biotech Co., Ltd. is covered by 10 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Hao WuChasing Securities
Pei ChengChina Galaxy Securities Co., Ltd.
Feifei XuChina Merchants Securities Co. Ltd.